Oncimmune Holdings PLC Initiation of a Multi-Centre Trial in China (5818Y)
10 May 2019 - 4:00PM
UK Regulatory
TIDMONC
RNS Number : 5818Y
Oncimmune Holdings PLC
10 May 2019
10 May 2019
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Initiation of a Multi-Centre Trial of EarlyCDT(R) -Lung in
China
Oncimmune Holdings plc (AIM: ONC.L), a leader in the
development, manufacture and commercialisation of personalised
immunodiagnostics for the screening, detection and care of cancer,
and its partner, Genostics Company Limited ("Genostics"), today
announce the start of a multi-centre case control study on early
lung cancer detection (for screening and nodules) in the People's
Republic of China using an extended panel of autoantibodies to
accommodate variations in the biomarkers expressed on cancer cells
in Asian populations.
The study will be led by Professor Bai, Professor and Chair of
the Department of Pulmonary Medicine, Zhongshan Hospital, Fudan
University and will study approximately 1,000 early lung cancers at
five leading academic health centres across China. The results are
expected in the fourth quarter of 2019 and will be used to support
Oncimmune's application for approval of EarlyCDT-Lung with the
China Food and Drug Administration.
Dr Adam M Hill, CEO of Oncimmune commented: "This study is part
of our ongoing programme to support the introduction of
EarlyCDT-Lung in China, which is progressing to schedule. We
welcome this initiative and the commitment of our partner Genostics
in supporting the introduction of EarlyCDT-Lung into what is one of
the world's largest markets."
Dr Cheung To, Chairman of Gene Group, said: "For more than 20
years, we have been committed to bringing the world's most
cutting-edge technologies and products into China. EarlyCDT-Lung is
a unique and innovative product. This China-wide validation study
in the Chinese population will help with EarlyCDT-Lung's future
effective commercialisation and accelerate the introduction of an
early lung cancer screening program in China, benefiting Chinese
patients and families."
-Ends-
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Mike Seabrook
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5700
About Oncimmune
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and
commercialisation of cancer specific immunodiagnostics for the
screening, detection and care of cancer. Oncimmune also develops
precision medicine and patient stratification tools for leading
pharmaceutical multinationals in both immuno-oncology and
autoimmune disease. Oncimmune is working to change how cancer is
diagnosed and treated. Its patented technology detects evidence of
the body's natural response to cancer, enabling detection four
years or more before standard clinical diagnosis. Oncimmune's tests
facilitate clinical decision-making and are complementary to
diagnostic technologies, making them valuable additions to
established and new care pathways. Oncimmune partners with leading
developers and distributors to make our technology available
globally.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT-Lung and EarlyCDT-Liver. To date, over 155,000 tests have
been performed for patients worldwide and EarlyCDT-Lung is being
used in the largest-ever randomised trial for the early detection
of lung cancer using biomarkers, the National Health Service (NHS)
ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune,
headquartered at its laboratory facility in Nottingham, UK, has a
discovery research centre in Dortmund, Germany and a CLIA lab in
Kansas, US as well as offices in London, UK and Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
What is EarlyCDT-Lung?
A blood test using a panel of seven immunogenic proteins for the
testing of tumour-related antibodies specific to lung cancer.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSSAFMUFUSELI
(END) Dow Jones Newswires
May 10, 2019 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024